In addition, the longest follow-up in metastatic melanoma patients treated with the anti-programmed death 1 (PD-1) monoclonal antibodies, pembrolizumab and nivolumab, reported that 30% of patients were alive at five years [4,5]. The gene discussed is PDCD1; the disease is metastatic melanoma.